Entia, a London, UK-based medical technology company, raised $12m in funding.
The round was led by BGF, with participation from existing seed investors including Parkwalk and Sussex Place Ventures.
The company intends to use the funds to launch Entia Liberty, a virtual oncology solution that allows patients to perform their own blood tests at home so remote healthcare teams can monitor and help manage the haematological toxicity of cancer treatment. It is at late stage development, pending regulatory approval and not currently available for sale.
Led by founder and CEO Dr Toby Basey-Fisher, Entia has built partnerships with healthcare institutions such as The Christie NHS Foundation Trust. In addition, Pfizer UK recently announced its partnership with the company in which it has committed to make Entia’s virtual monitoring service available in the UK for metastatic breast cancer patients in 2022, following regulatory approval.
Prior to this new investment, the company has raised over $13m to date, including major investment from Innovate UK as part of its Biomedical Catalyst programme.
FinSMEs
02/08/2023